Introgen to Host Conference Call with Clinical Investigators toDiscuss Phase III Data and Advexin Registration ActivitiesAUSTIN, Texas--(BUSINESS WIRE)--Jul 8, 2008 - Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that it will host a conference call with management and invited clinical experts on Thursday, July 10, 2008 at 3:30 p.m. ET.
Introgen management will discuss its recent ADVEXIN regulatory approval filings and phase III clinical data. In addition, several clinical investigators will be available to respond to questions. These clinicians to include, Dr. Jack Roth, inventor of ADVEXIN and professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic & Cardiovascular Surgery, Section Chief, Thoracic Molecular Oncology, and Director, W.M. Keck Cancer Center for Innovative Cancer Therapies, M.D. Anderson Cancer Center, Houston, TX, Dr. John Nemunaitis, a principal investigator of Introgen's phase III study and medical director, Mary Crowley Cancer Research Center at Baylor-Charles A. Sammons Cancer Center, Dallas, TX, Dr. John Hamm, Medical Director, Louisville Oncology at Norton Healthcare, Louisville, KY, and Dr. Jarrard Goodwin, Director, Sylvester Comprehensive Cancer Center/University of Miami Hospital and Clinics and Sylvester Professor, Department of Otolaryngology-Head and Neck Surgery.
The call will be held on Thursday, July 10, 2008, at 3:30 p.m. Eastern Time. The call will be available via Introgen's Web site at www.introgen.com. The call may also be accessed by dialing 1-877-493-1228 or 1-706-643-1852, conference ID number 55392696. For those unable to listen to the broadcast live, the call will be archived on Introgen's website.
About Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility. In June 2008 Introgen submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting marketing approval for ADVEXIN p53 therapy to treat recurrent, refractory head and neck cancer. Simultaneously, Gendux Molecular Limited, an Introgen subsidiary, submitted a Marketing Authorization Application (MAA) to the European Medicines Evaluation Agency (EMEA) for the same indication. ADVEXIN represents the first of a new class of tumor suppressor cancer therapy and is the first of its kind to be submitted for regulatory approval in the United States and Europe.
Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to the success of Introgen's regulatory filings. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.>
Posted: July 2008